Clinical Trial Update: FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing FDA018-ADC against investigator's choice chemotherapy for locally advanced, recurrent, or metastatic triple-negative breast cancer is ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• FDA018-ADC
• Investigator's Choice Chemotherapy

Snippet

Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING